Search

Your search keyword '"Jordan, Stanley C"' showing total 981 results
Start Over Author "Jordan, Stanley C"
981 results on '"Jordan, Stanley C"'

1. Cell-free DNA for the detection of kidney allograft rejection

Author

Aubert, Olivier, Ursule-Dufait, Cindy, Brousse, Romain, Gueguen, Juliette, Racapé, Maud, Raynaud, Marc, Van Loon, Elisabet, Pagliazzi, Angelica, Huang, Edmund, Jordan, Stanley C., Chavin, Kenneth D., Gupta, Gaurav, Kumar, Dhiren, Alhamad, Tarek, Anand, Sanjiv, Sanchez-Garcia, Jorge, Abdalla, Basmah A., Hogan, Julien, Garro, Rouba, Dadhania, Darshana M., Jain, Pranjal, Mandelbrot, Didier A., Naesens, Maarten, Dandamudi, Raja, Dharnidharka, Vikas R., Anglicheau, Dany, Lefaucheur, Carmen, and Loupy, Alexandre

Published
2024
Full Text
View/download PDF

2. Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis

Author

Ebinger, Joseph E, Joung, Sandy, Liu, Yunxian, Wu, Min, Weber, Brittany, Claggett, Brian, Botting, Patrick G, Sun, Nancy, Driver, Matthew, Kao, Yu Hung, Khuu, Briana, Wynter, Timothy, Nguyen, Trevor-Trung, Alotaibi, Mona, Prostko, John C, Frias, Edwin C, Stewart, James L, Goodridge, Helen S, Chen, Peter, Jordan, Stanley C, Jain, Mohit, Sharma, Sonia, Fert-Bober, Justyna, Van Eyk, Jennifer E, Minissian, Margo B, Arditi, Moshe, Melmed, Gil Y, Braun, Jonathan G, McGovern, Dermot PB, Cheng, Susan, and Sobhani, Kimia

Subjects
Prevention, Immunization, Infectious Diseases, Vaccine Related, Clinical Research, Emerging Infectious Diseases, Infection, Good Health and Well Being, Academic Medical Centers, Adult, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Cohort Studies, Demography, Female, Health Personnel, Humans, Hypertension, Immunoglobulin G, Longitudinal Studies, Male, Middle Aged, Prospective Studies, SARS-CoV-2, Vaccination, hypertension, infectious diseases, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

ObjectivesWe sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination.DesignThis study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics.SettingA large, multisite academic medical centre in Southern California, USA.ParticipantsA total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection.ResultsVaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R2=0.133), with a 1.74±0.11 SD higher IgG-S response (p

Published
2022

6. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.

Author

Schinstock, Carrie A, Mannon, Roslyn B, Budde, Klemens, Chong, Anita S, Haas, Mark, Knechtle, Stuart, Lefaucheur, Carmen, Montgomery, Robert A, Nickerson, Peter, Tullius, Stefan G, Ahn, Curie, Askar, Medhat, Crespo, Marta, Chadban, Steven J, Feng, Sandy, Jordan, Stanley C, Man, Kwan, Mengel, Michael, Morris, Randall E, O'Doherty, Inish, Ozdemir, Binnaz H, Seron, Daniel, Tambur, Anat R, Tanabe, Kazunari, Taupin, Jean-Luc, and O'Connell, Philip J

Subjects
Humans, Antilymphocyte Serum, Isoantibodies, Immunosuppression, Kidney Transplantation, Consensus, Graft Rejection, Tissue Donors, Societies, Medical, Societies, Medical, Surgery, Medical and Health Sciences
Abstract

With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed to improve patient outcomes.

Published
2020

8. Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant

Author

Redfield, Robert R, Jordan, Stanley C, Busque, Stephan, Vincenti, Flavio, Woodle, E Steve, Desai, Niraj, Reed, Elaine F, Tremblay, Simon, Zachary, Andrea A, Vo, Ashley A, Formica, Richard, Schindler, Thomas, Tran, Ha, Looney, Caroline, Jamois, Candice, Green, Cherie, Morimoto, Alyssa, Rajwanshi, Richa, Schroeder, Aaron, Cascino, Matthew D, Brunetta, Paul, and Borie, Dominic

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Kidney Disease, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Renal and urogenital, Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized, Antigens, CD20, Antineoplastic Agents, Immunological, Cohort Studies, Desensitization, Immunologic, Female, Follow-Up Studies, Graft Survival, HLA Antigens, Humans, Kidney Failure, Chronic, Kidney Transplantation, Male, Maximum Tolerated Dose, Middle Aged, Patient Selection, Prognosis, Risk Factors, Tissue Distribution, Young Adult, alloantibody, B cell biology, clinical research, practice, clinical trial, immunosuppressant - fusion proteins and monoclonal antibodies, B cell specific, immunosuppression, immune modulation, kidney transplantation, nephrology, pharmacology, clinical research/practice, immunosuppressant - fusion proteins and monoclonal antibodies: B cell specific, immunosuppression/immune modulation, kidney transplantation/nephrology, Medical and Health Sciences, Surgery, Clinical sciences
Abstract

The limited effectiveness of rituximab plus intravenous immunoglobulin (IVIG) in desensitization may be due to incomplete B cell depletion. Obinutuzumab is a type 2 anti-CD20 antibody that induces increased B cell depletion relative to rituximab and may therefore be more effective for desensitization. This open-label phase 1b study assessed the safety, pharmacokinetics, and pharmacodynamics of obinutuzumab in highly sensitized patients with end-stage renal disease. Patients received 1 (day 1, n = 5) or 2 (days 1 and 15; n = 20) infusions of 1000-mg obinutuzumab followed by 2 doses of IVIG on days 22 and 43. Eleven patients received additional obinutuzumab doses at the time of transplant and/or at week 24. The median follow-up duration was 9.4 months. Obinutuzumab was well tolerated, and most adverse events were grade 1-2 in severity. There were 11 serious adverse events (SAEs) in 9 patients (36%); 10 of these SAEs were infections and 4 occurred after kidney transplant. Obinutuzumab plus IVIG resulted in profound peripheral B cell depletion and appeared to reduce B cells in retroperitoneal lymph nodes. Reductions in anti-HLA antibodies, number of unacceptable antigens, and the calculated panel reactive antibody score as centrally assessed using single-antigen bead assay were limited and not clinically meaningful for most patients (NCT02586051).

Published
2019

10. Evidence of premature lymphocyte aging in people with low anti-spike antibody levels after BNT162b2 vaccination

Author

Huang, Yapei, Shin, Juliana E., Xu, Alexander M., Yao, Changfu, Joung, Sandy, Wu, Min, Zhang, Ruan, Shin, Bongha, Foley, Joslyn, Mahov, Simeon B., Modes, Matthew E., Ebinger, Joseph E., Driver, Matthew, Braun, Jonathan G., Jefferies, Caroline A., Parimon, Tanyalak, Hayes, Chelsea, Sobhani, Kimia, Merchant, Akil, Gharib, Sina A., Jordan, Stanley C., Cheng, Susan, Goodridge, Helen S., and Chen, Peter

Published
2022
Full Text
View/download PDF

14. Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study

Author

Orandi, Babak J, Luo, Xun, King, Elizabeth A, Garonzik-Wang, Jacqueline M, Bae, Sunjae, Montgomery, Robert A, Stegall, Mark D, Jordan, Stanley C, Oberholzer, Jose, Dunn, Ty B, Ratner, Lloyd E, Kapur, Sandip, Pelletier, Ronald P, Roberts, John P, Melcher, Marc L, Singh, Pooja, Sudan, Debra L, Posner, Marc P, El-Amm, Jose M, Shapiro, Ron, Cooper, Matthew, Lipkowitz, George S, Rees, Michael A, Marsh, Christopher L, Sankari, Bashir R, Gerber, David A, Nelson, Paul W, Wellen, Jason, Bozorgzadeh, Adel, Gaber, A Osama, and Segev, Dorry L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Kidney Disease, Clinical Research, Organ Transplantation, Transplantation, Renal and urogenital, Adult, Blood Group Incompatibility, Case-Control Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Survival, HLA Antigens, Hospitalization, Humans, Isoantibodies, Kidney Failure, Chronic, Kidney Function Tests, Kidney Transplantation, Living Donors, Male, Middle Aged, Patient Readmission, Postoperative Complications, Prognosis, Risk Factors, clinical research, practice, desensitization, economics, health services and outcomes research, hospital readmission, kidney transplantation, nephrology, kidney transplantation: living donor, organ transplantation in general, quality of care, care delivery, clinical research/practice, kidney transplantation/nephrology, quality of care/care delivery, Medical and Health Sciences, Surgery, Clinical sciences, Immunology
Abstract

Thirty percent of kidney transplant recipients are readmitted in the first month posttransplantation. Those with donor-specific antibody requiring desensitization and incompatible live donor kidney transplantation (ILDKT) constitute a unique subpopulation that might be at higher readmission risk. Drawing on a 22-center cohort, 379 ILDKTs with Medicare primary insurance were matched to compatible transplant-matched controls and to waitlist-only matched controls on panel reactive antibody, age, blood group, renal replacement time, prior kidney transplantation, race, gender, diabetes, and transplant date/waitlisting date. Readmission risk was determined using multilevel, mixed-effects Poisson regression. In the first month, ILDKTs had a 1.28-fold higher readmission risk than compatible controls (95% confidence interval [CI] 1.13-1.46; P

Published
2018

15. The impact of competing risks in kidney allograft failure prediction

Author

Truchot, Agathe, primary, Raynaud, Marc, additional, Helantera, Ilkka, additional, Aubert, Olivier, additional, Kamar, Nassim, additional, Legendre, Christophe, additional, Hertig, Alexandre, additional, Buchler, Matthias, additional, Crespo, Marta, additional, Akalin, Enver, additional, Soler Pujol, Gervasio, additional, Ribeiro de Castro, Maria Cristina, additional, Matas, Arthur J., additional, Ulloa, Camilo, additional, Jordan, Stanley C., additional, Huang, Edmund, additional, Juric, Ivana, additional, Basic-Jukic, Nikolina, additional, Coemans, Maarten, additional, Naesens, Maarten, additional, Friedewald, John J., additional, Tedesco Silva, Helio, additional, Lefaucheur, Carmen, additional, Segev, Dorry L., additional, Collins, Gary S., additional, and Loupy, Alexandre, additional

Published
2024
Full Text
View/download PDF

17. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study

Author

Raynaud, Marc, Aubert, Olivier, Divard, Gillian, Reese, Peter P, Kamar, Nassim, Yoo, Daniel, Chin, Chen-Shan, Bailly, Élodie, Buchler, Matthias, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Crespo, Marta, Silva, Helio Tedesco, Jr, Linhares, Kamilla, Ribeiro de Castro, Maria Cristina, Soler Pujol, Gervasio, Empana, Jean-Philippe, Ulloa, Camilo, Akalin, Enver, Böhmig, Georg, Huang, Edmund, Stegall, Mark D, Bentall, Andrew J, Montgomery, Robert A, Jordan, Stanley C, Oberbauer, Rainer, Segev, Dorry L, Friedewald, John J, Jouven, Xavier, Legendre, Christophe, Lefaucheur, Carmen, and Loupy, Alexandre

Published
2021
Full Text
View/download PDF

25. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation

Author

Raynaud, Marc, Aubert, Olivier, Reese, Peter P., Bouatou, Yassine, Naesens, Maarten, Kamar, Nassim, Bailly, Élodie, Giral, Magali, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Gupta, Gaurav, Akalin, Enver, Yoo, Daniel, Chin, Chen-Shan, Proust-Lima, Cécile, Böhmig, Georg, Oberbauer, Rainer, Stegall, Mark D., Bentall, Andrew J., Jordan, Stanley C., Huang, Edmund, Glotz, Denis, Legendre, Christophe, Montgomery, Robert A., Segev, Dorry L., Empana, Jean-Philippe, Grams, Morgan E., Coresh, Josef, Jouven, Xavier, Lefaucheur, Carmen, and Loupy, Alexandre

Published
2021
Full Text
View/download PDF

30. Cover Image

Author

Jordan, Stanley C., primary, Joung, Sandy Y., additional, Wang, Minhao, additional, Tran, Teresa Anh, additional, Bravo, Michelle, additional, Masoom, Hibah, additional, Chang, Christine, additional, Mendez, Marilyn, additional, Sun, Nancy, additional, Patel, Jignesh, additional, Kittleson, Michelle, additional, Frias, Edwin, additional, Prostko, John C., additional, Ebinger, Joseph E., additional, Cheng, Susan, additional, and Sobhani, Kimia, additional

Published
2024
Full Text
View/download PDF

38. Assessing the post hoc effectiveness of tixagevimab−cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients

Author

Jordan, Stanley C., primary, Joung, Sandy Y., additional, Wang, Minhao, additional, Tran, Teresa Anh, additional, Bravo, Michelle, additional, Masoom, Hibah, additional, Chang, Christine, additional, Mendez, Marilyn, additional, Sun, Nancy, additional, Patel, Jignesh, additional, Kittleson, Michelle, additional, Frias, Edwin, additional, Prostko, John C., additional, Ebinger, Joseph E., additional, Cheng, Susan, additional, and Sobhani, Kimia, additional

Published
2023
Full Text
View/download PDF

41. Characterizing the risk of human leukocyte antigen-incompatible living donor kidney transplantation in older recipients

Author

Long, Jane J., primary, Motter, Jennifer D., additional, Jackson, Kyle R., additional, Chen, Jennifer, additional, Orandi, Babak J., additional, Montgomery, Robert A., additional, Stegall, Mark D., additional, Jordan, Stanley C., additional, Benedetti, Enrico, additional, Dunn, Ty B., additional, Ratner, Lloyd E., additional, Kapur, Sandip, additional, Pelletier, Ronald P., additional, Roberts, John P., additional, Melcher, Marc L., additional, Singh, Pooja, additional, Sudan, Debra L., additional, Posner, Marc P., additional, El-Amm, Jose M., additional, Shapiro, Ron, additional, Cooper, Matthew, additional, Verbesey, Jennifer E., additional, Lipkowitz, George S., additional, Rees, Michael A., additional, Marsh, Christopher L., additional, Sankari, Bashir R., additional, Gerber, David A., additional, Wellen, Jason R., additional, Bozorgzadeh, Adel, additional, Gaber, A. Osama, additional, Heher, Eliot C., additional, Weng, Francis L., additional, Djamali, Arjang, additional, Helderman, J. Harold, additional, Concepcion, Beatrice P., additional, Brayman, Kenneth L., additional, Oberholzer, Jose, additional, Kozlowski, Tomasz, additional, Covarrubias, Karina, additional, Massie, Allan B., additional, McAdams-DeMarco, Mara A., additional, Segev, Dorry L., additional, and Garonzik-Wang, Jacqueline M., additional

Published
2023
Full Text
View/download PDF

44. Management of the sensitized pediatric renal transplant candidate.

Author

Puliyanda, Dechu P. and Jordan, Stanley C.

Subjects
*KIDNEY transplantation, *TRANSPLANTATION of organs, tissues, etc., *CHILD patients, *GRAFT rejection, *OVERALL survival
Abstract

Kidney transplantation is the treatment of choice for patients with ESRD as it is associated with improved patient survival and better quality of life, especially in children. There are several barriers to a successful transplant including organ shortage, anatomic barriers, and immunologic barriers. One of the biggest immunologic barriers that precludes transplantation is sensitization, when patients have antibodies prior to transplantation, resulting in positive crossmatches with donor. 30%–40% of adult patients on the wait list are sensitized. There is a growing number of pediatric patients on the wait list who are sensitized. This poses a unique challenge to the pediatric transplant community. Therefore, attempts to perform desensitization to remove or suppress pathogenic HLA antibodies resulting in acceptable crossmatches, and ultimately a successful transplant, while reducing the risk of acute rejection, are much needed in these children. This review article aims to address the management of such patients both prior to transplantation, with strategies to overcome sensitization, and after transplantation with monitoring for allograft rejection and other complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Assessing the post hoc effectiveness of tixagevimab−cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients.

Author

Jordan, Stanley C., Joung, Sandy Y., Wang, Minhao, Tran, Teresa Anh, Bravo, Michelle, Masoom, Hibah, Chang, Christine, Mendez, Marilyn, Sun, Nancy, Patel, Jignesh, Kittleson, Michelle, Frias, Edwin, Prostko, John C., Ebinger, Joseph E., Cheng, Susan, and Sobhani, Kimia

Subjects
*TRANSPLANTATION of organs, tissues, etc., *INFECTION prevention, *ANGIOTENSIN converting enzyme, *COVID-19, *IMMUNOCOMPROMISED patients
Abstract

Background: Tixagevimab−cilgavimab (Tix‐Cil) was authorized for prophylaxis against COVID‐19 in immunocompromised patients from December 2021 through January 2023. Real‐world effectiveness for solid organ transplant (SOT) recipients has been unclear. Methods: We enrolled 911 SOT recipients into a longitudinal COVID‐19 serology study, of whom 381 (42%) received ≥1 dose of Tix‐Cil. We collected and analyzed data on incident SARS‐CoV‐2 infections and antibody kinetics for all patients from January 2022 to March 2023, including periods dominated by Omicron BA and BQ subvariants. Results: Over 253 ± 131 days of follow‐up, there were 324 new‐onset SARS‐CoV‐2 infections: 117 (31%) in Tix‐Cil treated and 207 (39%) in Tix‐Cil untreated patients (p =.012). In analyses adjusting for demographic, clinical, and COVID‐19 exposure factors, any Tix‐Cil treatment was associated with lower infection risk (OR 0.52, 95% CI 0.27–0.96, p =.039) throughout the surveillance period including when more resistant BQ.1 and BQ.1.1 subvariants had emerged (12/1/2022 onwards). Among treated patients, receiving a Tix‐Cil dose was associated with substantial and sustained increase in anti‐spike IgG antibody and angiotensin‐converting enzyme 2 binding inhibition levels (Abbott Architect assay) that together also demonstrated association with lower infection risk (p =.042). During the full surveillance period, the frequency of infections requiring hospitalization was low overall (N = 26, 2.9% of the total cohort) and not significantly different between Tix‐Cil recipients (N = 12, 3.2% of treated patients) and non‐Tix‐Cil recipients (N = 14, 2.6% of untreated patients) with unadjusted p =.31 for between‐group difference. Conclusion: In a large cohort of SOT recipients, we found that Tix‐Cil reduced infection risk even amidst emergent Omicron subvariants. Additionally, the extent of measurable humoral response to Tix‐Cil may indicate relative effectiveness. Pre‐exposure monoclonal antibody therapy may represent a strategy that will continue to offer clinical benefit for immunocompromised persons who are known to derive limited protection from vaccinations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results